Refine by
Breast Biopsy Articles & Analysis
14 news found
October marks a month dedicated to a cause close to the core of everything which we do at Cirdan: Breast Cancer Awareness. This month will see a surge in activism surrounding breast cancer awareness and a push for finding a cure from around the globe. The fight to treat and cure breast cancer continues constantly, and we pride ourselves in taking part in the fight to save lives. Breast cancer ...
Orsi Summary: Underscores the merit of identifying HER2 heterogeneity using digitized H&E stained breast biopsy slide images alone. We have established this index to be a robust prognostic indicator in determining PFS in ER+ carcinomas. ...
This partnership allows Inspirata and SpIntellx customers the seamless integration of Dynamyx and HistoMapr-Breast, resulting in a more efficient breast core-biopsy workflow with access to unbiased and advanced spatial analytics powered by explainable AI (xAI). ...
We truly believe that Imagio® can make a difference in both diagnostic confidence and patient experiences.” Breast biopsy procedures caused by false-positive diagnostic assessments in the United States cost the healthcare system more than $2 billion per year. ...
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS, for the preservation of extracellular vesicle (EV) RNA, and cell-free DNA (cfDNA) in urine, collected with Colli-Pee. Novosanis hereby offers a solution for applications in the field of oncology research and ...
(Seno)’s Imagio opto-acoustic ultrasound (OA/US) breast imaging provides significantly better specificity than ultrasound alone. ...
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. ...
(Seno) has launched its CONFIDENCE registry to evaluate the efficacy of imaging with opto-acoustic/ultrasound (OA/US) to diagnose breast abnormalities including cancer using its groundbreaking Imagio® Breast Imaging System. ...
In addition, funds will be used to complete the development of a new generation of medical devices designed to improve MRI utilization in the breast biopsy market. “With the recent FDA 510(k) clearance of Nova, our multimodality fiducial marker, these funds position us to maximize our growth opportunities,” said Andrew Bright, C4 Imaging’s ...
Breast biopsy procedures caused by false-positive diagnostic assessments in the United States cost the healthcare system more than $2 billion per year.[i] Seno’s Imagio® technology could mitigate that by giving providers additional real-time information regarding suspicious breast masses and increased confidence to make a better ...
Dr. Elizabeth Revesz has a unique background as an artist and sculptor. She was able to translate her precision, and her ability to see things in three dimensions, into a highly successful career in medicine. But once in the medical field, Dr. Revesz went further to find her true calling. “Medicine is great, but surgery is actually where I feel the most comfortable,” the physician ...
Dr. Rabia Z. Bhatti with the AMITA Resurrection Medical Center has always had a strong interest in the art of surgery. “I actually love the way that patients recover,” she explained. “There’s a gratification behind treating patients and watching them get better. And after practicing general surgery for 15 years, I realized I could provide even better care to my patients by ...
“Multiple publications and presentations over the course of 2018 substantially strengthen the body of evidence emphasizing the economic costs of unnecessary breast biopsies and the power of our Imagio Breast Imaging System to potentially reduce the number of these procedures,” said Thomas Umbel, President and CEO of Seno Medical ...
(the developer of the WEB Aneurysm Embolization Device, acquired by Terumo in 2016), MicroVention (which developed the HydroCoil Aneurysm Embolization System and various other cerebrovascular products, acquired by Terumo in 2006) and SenoRx (developer of the Enspire Breast Biopsy System, acquired by CR Bard in 2010),” said Bob Rosenbluth, Inceptus ...